Oral Drugs Related with Muscle Wasting and Sarcopenia. A Review

Subject Area: Pharmacology
Lluis Campins; Marcella Camps; Ariadna Riera; Eulogio Pleguezuelos; Juan Carlos Yebenes; Mateu Serra-Prat
Pharmacology (2017) 99 (1-2): 1–8.

Sarcopenia is a geriatric syndrome characterized by progressive and generalized loss of skeletal muscle mass and function. Reported prevalence of this geriatric syndrome, differs depending on the definition, the population and the method used to identify sarcopenia. The causes of sarcopenia are multifactorial, and can include genetic influence, immobility or disuse, endocrine factors, inflammation and nutritional deficiencies. These disorders involve an imbalance between anabolic and catabolic pathways that rules muscle mass. Many drugs taken regularly for common conditions may interact with some mechanisms that can alter the balance between protein synthesis and degradation. This may lead to a harmful or a beneficial effect on muscle mass and strength. Widely prescribed drugs could play an important role during the time of onset and development of sarcopenia. In this paper, we reviewed the current understanding of how can drugs contribute positively or negatively on sarcopenia and muscle wasting. We decided to focus this review on oral common drugs, which are usually prescribed in older adults, leaving aside other drugs as hormone therapy.
Keywords: Sarcopenia, Angiotensin-converting enzyme inhibitors, Statins, Antidiabetic drugs, Vitamin D, Muscle wasting
BUY THIS ARTICLE

 

© thepharmacology.org